Cingulate Completes Final FDA Study for CTx-1301 ADHD Treatment
On January 7, 2025, Cingulate Inc. (NASDAQ:CING) announced the successful completion of its final FDA-required study for CTx-1301 (dexmethylphenidate) aimed at treating Attention Deficit Hyperactivity Disorder (ADHD). This study, specifically a food effect study, represents a significant milestone in the development of the drug. The study involved the administration of a single 50mg dose of […]
More Stories
Trump Announces EPA Will Roll Back Biden-Era Methane Regulations on Oil and Gas Producers
By Tom Gantert President Donald Trump announced Tuesday night in Lubbock, Texas, that his administration would roll back Biden-era methane...
Treasury Department Ends Ownership Reporting for US Small Businesses
By Owen Evans The Treasury Department on Aug. 11 finalized a rule permanently exempting U.S. companies and individuals from reporting...
US Consumer Confidence Rebounds Sharply in October: Conference Board
By Andrew Moran U.S. consumer confidence rebounded sharply in October, logging its first increase in four months, according to The...
Microsoft Offers Voluntary Buyouts to 60,000 Employees
By Andrew Moran Microsoft is offering voluntary buyouts to about 60,000 employees, around one-quarter of its total workforce, the software...
SBS Executives Questioned on Why Outlet Refers to Hamas as ‘Militants’ Not ‘Terrorists’
By Crystal-Rose Jones Executives at Australia’s multicultural Special Broadcasting Service (SBS) were asked to explain why the outlet does not...
What a New Roof Really Costs in Texas: A 2026 Budget Guide
The roof is the most expensive part of a house that most owners never look at. One spring storm can...